- Trials with a EudraCT protocol (29)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
29 result(s) found for: Hyaline membrane disease.
Displaying page 1 of 2.
EudraCT Number: 2018-003233-14 | Sponsor Protocol Number: 18CH129 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:CHU de Saint Etienne | |||||||||||||||||||||||
Full Title: Evaluation of the neonatal autonomic stress during intubations under Propofol in a population of premature infants under 33 w’GA | |||||||||||||||||||||||
Medical condition: population of premature infants under 33 w’GA requiring intubation for the administration of exogenous surfactant | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005429-21 | Sponsor Protocol Number: OPTIMIST-Aprotocol | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Menzies Research Institute Tasmania | |||||||||||||
Full Title: Multicentre randomised controlled trial of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation on continuous positive airway pressure (CPAP) | |||||||||||||
Medical condition: Infant respiratory distress syndrome, also known as hyaline membrane disease. | |||||||||||||
|
|||||||||||||
Population Age: In utero, Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA SI (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004160-58 | Sponsor Protocol Number: CHASAP | Start Date*: 2021-06-11 | ||||||||||||||||
Sponsor Name:Centre hospitalier intercommunal de Créteil | ||||||||||||||||||
Full Title: Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a multicenter prospective randomized double-blind placebo-controlled trial | ||||||||||||||||||
Medical condition: Pregnant women with chronic hypertension | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000489-37 | Sponsor Protocol Number: SURF-04-01 | Start Date*: 2005-08-26 |
Sponsor Name:Nektar Therapeutics | ||
Full Title: An open label, randomized, controlled study to evaluate the safety and efficacy of aerosolized surfactant, Curosurf®, delivered via nasal continuous positive airway pressure pulmonary drug delivery... | ||
Medical condition: The medical condition for this application is the Respiratory Distress Syndrome (RDS). RDS, also known as hyaline membrane disease, is characterized by lung immaturity and surfactant deficiency a... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005883-78 | Sponsor Protocol Number: CHRD1520 | Start Date*: 2021-02-05 | |||||||||||||||||||||||||||||||
Sponsor Name:Hospital Center rené Dubos | |||||||||||||||||||||||||||||||||
Full Title: Comparison of Prednisolone and Dexamethasone on D28 mortality in patients on oxygen therapy with CoViD-19 | |||||||||||||||||||||||||||||||||
Medical condition: Care of severe forms of CoViD-19 from the transitional phase and the onset of the inflammatory phase with corticosteroids | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000775-17 | Sponsor Protocol Number: PI11-0143 | Start Date*: 2012-11-21 | |||||||||||
Sponsor Name:Jesús Villar Hernández | |||||||||||||
Full Title: A comparative, randomised controlled trial for evaluating the efficacy of dexamethasone administration in the treatment of patients with the Acute Respiratory Distress Syndrome | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004442-16 | Sponsor Protocol Number: cro524 | Start Date*: 2006-11-29 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Modulation of lung injury complicating lung resection | |||||||||||||
Medical condition: Acute respiratory distress syndrome, Acute Lung Injury, Ventilator-Induced Lung Injury | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002022-20 | Sponsor Protocol Number: NL61945.029.17 | Start Date*: 2017-07-27 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: The effect of inspiratory oxygen fraction on the ratio of partial arterial oxygen pressure and inspiratory oxygen fraction (PaO2/FiO2 ratio) in mechanically ventilated patients with and without mil... | |||||||||||||
Medical condition: We investigate the PaO2/FiO2 ratio in patients without and with mild to moderate ARDS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002494-28 | Sponsor Protocol Number: 6 | Start Date*: 2023-05-18 | |||||||||||
Sponsor Name:Consorcio Centro de Investigacion Biomedica en Red, (CIBER) | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of intravenous metoprolol in patients with Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
Medical condition: Intensive Care Unit patients with Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006644-27 | Sponsor Protocol Number: CARR-ARDS-2021 | Start Date*: 2023-02-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA UDINE | |||||||||||||
Full Title: Efficacy and safety of anakinra in non-COVID-19 related ARDS. ESKA study. | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005306-25 | Sponsor Protocol Number: Pioneer | Start Date*: 2021-09-15 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: PIrfenidone to prevent fibrOsis in ARDS. A RaNdomizEd controllEd tRial (PIONEER) GR-2019-12371063 | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002913-16 | Sponsor Protocol Number: 0135-0347 | Start Date*: 2020-11-26 | |||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm. V | |||||||||||||
Full Title: The TRISTARDS trial - ThRombolysIS Therapy for ARDS A Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome caused by Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) AT (Ongoing) PT (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) PL (Completed) RO (Ongoing) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003486-19 | Sponsor Protocol Number: 1.002.20 | Start Date*: 2020-10-08 | ||||||||||||||||||||||||||
Sponsor Name:University of Dundee | ||||||||||||||||||||||||||||
Full Title: A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in patients with community acquired pneumonia and suspected or con... | ||||||||||||||||||||||||||||
Medical condition: Community acquired pneumonia with suspected or confirmed SARS-CoV-2 infection | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000598-95 | Sponsor Protocol Number: HS-20-674 | Start Date*: 2021-07-30 | |||||||||||
Sponsor Name:Camurus AB | |||||||||||||
Full Title: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002122-82 | Sponsor Protocol Number: UKER-COV2-01 | Start Date*: 2020-06-12 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Erlangen | ||||||||||||||||||
Full Title: Prospective open-label randomized controlled phase 2b clinical study in parallel groups for the assessment of efficacy and safety of immune therapy with COVID-19 convalescent plasma plus standard t... | ||||||||||||||||||
Medical condition: ARDS due to COVID-19 necessitating invasive mechanical ventilation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-004706-22 | Sponsor Protocol Number: ImlifidARDSe.01 | Start Date*: 2023-02-17 | ||||||||||||||||||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | ||||||||||||||||||||||||||||
Full Title: Imlifidase in ANCA-associated vasculitis | ||||||||||||||||||||||||||||
Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis with severe diffuse alveolar hemorrhage | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020403-75 | Sponsor Protocol Number: ACEmeVent-Pilot | Start Date*: 2011-10-24 | ||||||||||||||||
Sponsor Name:Universität Leipzig | ||||||||||||||||||
Full Title: ACE inhibitor for lung protection during mechanical Ventilation for acute lung injury - pilot trial | ||||||||||||||||||
Medical condition: acute lung injury, ALI/ARDS | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001420-34 | Sponsor Protocol Number: 0001 | Start Date*: 2020-04-14 | |||||||||||
Sponsor Name:Aarhus University | |||||||||||||
Full Title: Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial | |||||||||||||
Medical condition: Infection with COVID19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005863-29 | Sponsor Protocol Number: HelmetHeparin | Start Date*: 2021-07-15 | |||||||||||||||||||||
Sponsor Name:ASST FATEBENEFRATELLI SACCO | |||||||||||||||||||||||
Full Title: Nebulised heparin in COVID-19-related ARDS patients undergoing non-invasive ventilation with helmet cPAP: a prospective, randomised, double blind, placebo-controlled, multicentre study | |||||||||||||||||||||||
Medical condition: COVID-19-related Acute Respiratory Distress Syndrome (ARDS) patients undergoing non-invasive ventilation with helmet continuous positive airway pressure (cPAP) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001612-25 | Sponsor Protocol Number: REP0122 | Start Date*: 2022-10-12 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with ... | |||||||||||||
Medical condition: Acute Respiratory Distress Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
